Coronavirus InfectionsFRENCH ICUNCT04420286
Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
An observational study of Coronavirus Infections and COVID19 Outbreak in France, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
Trial summary
For preventing the overwhelming of ICU beds capacity during COVID-19 pandemic in France, national and regional Health-Care institutions decided to optimize the Intensive Care Unit beds availability by opening new ICU beds in institutions with and without prior ICU. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Coronavirus Infections, COVID19 Outbreak in France
- How many people
- 9,860 participants
- Where
- 1 siteFrance
- Study dates
- 6 May 2020to 31 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study is not based on patients but on hospital organisation to describe the origin of the ICU beds and human resources created during the COVID-19 outbreak in France.
Who may be able to join
- Hospital having ICU during COVID-19 outbreak in France
Who cannot join
- Hospital refuse to participate
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Study of the Increase in ICU Beds Capacity and Caregivers During COVID-19 Pandemic in France : the FRENCH ICU Study
For preventing the overwhelming of ICU beds capacity during COVID-19 pandemic in France, national and regional Health-Care institutions decided to optimize the Intensive Care Unit beds availability by opening new ICU beds in institutions with and without prior ICU. The Present study was design to retrospectively describe the origin of the ICU beds and human resources created during the COVID-19 outbreak in France.
Read the detailed description
Since December 2019, the SARS-CoV-2 coronavirus disease has caused a worldwide outbreak of respiratory illness that rapidly invaded leading the world (WHO). Its most severe form is dominated by an acute respiratory distress syndrome (ARDS) with other organ failures requiring mechanical ventilation and admission in Intensive Care Unit (ICU). With a wide pandemic effect and a long length of mechanical ventilation, the intensive care units were quickly full.
For preventing the overwhelming of ICU beds capacity, national and regional Health-Care institutions (then French Health minister, every Regional Health) decided to optimize the Intensive Care Unit beds availability by opening new ICU beds in institutions with and without prior ICU.
Daily ICU beds availability was assessed in each institution, and at the regional level to organize potential patient transfers across regional and national hospital. Moreover, an extraordinary mobilization and joint efforts of medical, paramedical and administrative staff allowed getting the caregivers for managing the most severe patients in each ICU. All physicians who could manage ICU patients were involved in this crisis. In this context, anesthesiologists (who have gotten an ICU education during their studies) were involved, as the surgical activity has been reduced to the vital procedures. This overall organization permitted the admission of more patients than the initial maximum national capacity of ICU beds.
- Conditions
- Coronavirus Infections, COVID19 Outbreak in France
- Keywords
- COVID-19, Critical care, Intensive Care
- Medical subject headings
- Coronavirus Infections, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Hospital having ICU beds | Hospital having ICU beds during COVID-19 outbreak in France |
What is being measured
The primary outcome is the main question the study is designed to answer.
origin of the ICU beds created during the COVID-19 outbreak in France.
Describe the origin of the ICU beds created during the COVID-19 outbreak in France.
Measured: DAY 0
Secondary outcomes (1)
Human Resources
Describe the human resources (medical and non-medical) mobilized to ensure that all acute patients could be managed (physicians according to their initial specialty, nurses and nursing auxiliaries).
Measured: DAY 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2020
- Study start6 May 2020
- Primary completion31 Dec 2020
- Study completion31 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Coronavirus InfectionsStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 9,860 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04420286
- Sponsor's protocol ID
- 30RC20_0117
- Acronym
- FRENCH ICU
- Status last verified
- Aug 2021
- First submitted
- 5 Jun 2020
- Last updated
- 4 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Lefrant JY, Fischer MO, Potier H, Degryse C, Jaber S, Muller L, Pottecher J, Charboneau H, Meaudre E, Lanot P, Bruckert V, Plaud B, Dureuil B, Samain E, Bouaziz H, Ecoffey C, Capdevila X; French ICU study investigators group. A national healthcare response to intensive care bed requirements during the COVID-19 outbreak in France. Anaesth Crit Care Pain Med. 2020 Dec;39(6):709-715. doi: 10.1016/j.accpm.2020.09.007. Epub 2020 Oct 5.
PubMed 33031979
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Increase in ICU Beds Capacity and Caregivers During COVID-19 Pandemic in France : the FRENCH ICU Study
- ClinicalTrials.gov ID
- NCT04420286
- Acronym / sponsor ID
- FRENCH ICU / 30RC20_0117
- Conditions
- Coronavirus Infections, COVID19 Outbreak in France
- Keywords
- COVID-19, Critical care, Intensive Care
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 9,860 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 6 May 2020 (actual)
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 31 Dec 2020 (actual)
- First posted
- 9 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
For preventing the overwhelming of ICU beds capacity during COVID-19 pandemic in France, national and regional Health-Care institutions decided to optimize the Intensive Care Unit beds availability by opening new ICU beds in institutions with and without prior ICU. The Present study was design to retrospectively describe the origin of the ICU beds and human resources created during the COVID-19 outbreak in France.
Detailed description
Since December 2019, the SARS-CoV-2 coronavirus disease has caused a worldwide outbreak of respiratory illness that rapidly invaded leading the world (WHO). Its most severe form is dominated by an acute respiratory distress syndrome (ARDS) with other organ failures requiring mechanical ventilation and admission in Intensive Care Unit (ICU). With a wide pandemic effect and a long length of mechanical ventilation, the intensive care units were quickly full.
For preventing the overwhelming of ICU beds capacity, national and regional Health-Care institutions (then French Health minister, every Regional Health) decided to optimize the Intensive Care Unit beds availability by opening new ICU beds in institutions with and without prior ICU.
Daily ICU beds availability was assessed in each institution, and at the regional level to organize potential patient transfers across regional and national hospital. Moreover, an extraordinary mobilization and joint efforts of medical, paramedical and administrative staff allowed getting the caregivers for managing the most severe patients in each ICU. All physicians who could manage ICU patients were involved in this crisis. In this context, anesthesiologists (who have gotten an ICU education during their studies) were involved, as the surgical activity has been reduced to the vital procedures. This overall organization permitted the admission of more patients than the initial maximum national capacity of ICU beds.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hospital having ICU beds | – | –Hospital having ICU beds during COVID-19 outbreak in France |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study is not based on patients but on hospital organisation to describe the origin of the ICU beds and human resources created during the COVID-19 outbreak in France.
Key inclusion criteria (1 listed)
- Hospital having ICU during COVID-19 outbreak in France
Key exclusion criteria (1 listed)
- Hospital refuse to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
origin of the ICU beds created during the COVID-19 outbreak in France.
Time frame: DAY 0
Describe the origin of the ICU beds created during the COVID-19 outbreak in France.
1 secondary outcome
Human Resources
Time frame: DAY 0
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2025.
- Results publication: PubMed 33031979Lefrant JY, Fischer MO, Potier H, Degryse C, Jaber S, Muller L, Pottecher J, Charboneau H, Meaudre E, Lanot P, Bruckert V, Plaud B, Dureuil B, Samain E, Bouaziz H, Ecoffey C, Capdevila X; French ICU study investigators group. A national healthcare response to intensive care bed requirements during the COVID-19 outbreak in France. Anaesth Crit Care Pain Med. 2020 Dec;39(6):709-715. doi: 10.1016/j.accpm.2020.09.007. Epub 2020 Oct 5.
- Individual participant dataSharing planned: No
Related trials for Coronavirus Infections
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronavirus Infections and COVID19 Outbreak in France, run by Centre Hospitalier Universitaire de Nīmes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
origin of the ICU beds created during the COVID-19 outbreak in France. (time frame: DAY 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04420286, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.